Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of anlotinib combined with TP as neoadjuvant therapy for resectable head and neck squamous cell carcinoma
ChiCTR2100046440Phase 2Recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, paclitaxel and cisplatin in head and neck squamous cell carcinoma (HNSCC), oropharyngeal squamous cell carcinoma (OPSCC), squamous cell carcinoma of the hypopharynx and 1 more, sponsored by Mianyang Central Hospital. Primary endpoint: Objective response rate. Started Jan 2021; status: recruiting.
02
Drugs
anlotinibpaclitaxelcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on ChiCTR2100046440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046440.